Related Experiment Videos
Adjuvant therapy for resectable rectal adenocarcinoma.
1Department of Radiation Oncology, Beth Israel Medical Center, New York, New York, USA.
Seminars in Surgical Oncology
|March 10, 2001
Summary
Surgical resection is the primary rectal cancer treatment. Adjuvant therapies, particularly preoperative chemoradiation, are improving outcomes by reducing recurrence and potentially enhancing survival for rectal cancer patients.
Area of Science:
- Oncology
- Surgical Oncology
- Radiation Oncology
Background:
- Surgical resection has been the standard treatment for rectal cancer for a century.
- Locoregional recurrence remains a significant challenge following conventional resection alone.
- Adjuvant therapy development has advanced significantly in recent decades.
Purpose of the Study:
- To review the role of adjuvant therapy in resectable rectal cancers.
- To provide an update on the status of ongoing randomized trials in rectal cancer treatment.
Main Methods:
- Review of existing literature on adjuvant therapy for rectal cancer.
- Analysis of current data from ongoing randomized clinical trials.
Main Results:
- Postoperative chemoradiation is the standard in the US for T3 or node-positive rectal cancer.
- Preoperative radiation, with or without chemotherapy, shows promise in decreasing local recurrence.
- Preoperative approaches may also improve sphincter preservation and overall survival rates.
Conclusions:
- Adjuvant therapy, especially preoperative chemoradiation, plays a crucial role in improving rectal cancer treatment outcomes.
- Ongoing trials are vital for further refining neoadjuvant and adjuvant strategies.
- Optimizing treatment for rectal cancer involves balancing surgical resection with effective adjuvant modalities.